111 related articles for article (PubMed ID: 27283845)
1. Higher priced drugs are not cost effective for diabetic macular edema, US study finds.
McCarthy M
BMJ; 2016 Jun; 353():i3253. PubMed ID: 27283845
[No Abstract] [Full Text] [Related]
2. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
O'Malley PG
Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
[No Abstract] [Full Text] [Related]
3. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
Jampol LM; Glassman AR; Bressler NM
JAMA Ophthalmol; 2015 Sep; 133(9):983-4. PubMed ID: 26087135
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data.
Holekamp N; Duff SB; Rajput Y; Garmo V
J Med Econ; 2020 Mar; 23(3):287-296. PubMed ID: 31502893
[No Abstract] [Full Text] [Related]
6. The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain.
Navarro-Navarro A; Salom D; Martínez-Toldos JJ; Udaondo P; Fernández-Martínez C; Gutiérrez-Arias L; Hervás A; Rodrigo R
Arch Soc Esp Oftalmol; 2017 May; 92(5):245-246. PubMed ID: 28215618
[No Abstract] [Full Text] [Related]
7. Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema.
Konidaris VE; Tsaousis KT; Al-Hubeshy Z; Pieri K; Deane J; Empeslidis T
Eye (Lond); 2017 Nov; 31(11):1629-1630. PubMed ID: 28622326
[No Abstract] [Full Text] [Related]
8. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015.
Hollingworth W; Jones T; Reeves BC; Peto T
BMJ Open; 2017 Oct; 7(10):e018289. PubMed ID: 29061629
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factors treatment of wet age-related macular degeneration: from neurophysiology to cost-effectiveness.
Vottonen P
Acta Ophthalmol; 2018 Feb; 96 Suppl A109():1-46. PubMed ID: 29468838
[No Abstract] [Full Text] [Related]
10. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema.
Wykoff CC; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4):308-12. PubMed ID: 27065368
[No Abstract] [Full Text] [Related]
11. Comparative effectiveness of anti-VEGF agents for diabetic macular edema.
Ollendorf DA; Colby JA; Pearson SD
Int J Technol Assess Health Care; 2013 Oct; 29(4):392-401. PubMed ID: 24290332
[TBL] [Abstract][Full Text] [Related]
12. An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective.
Meunier A; Opeifa O; Longworth L; Cox O; Bührer C; Durand-Zaleski I; Kelly SP; Gale RP
Eye (Lond); 2024 Jul; 38(10):1917-1925. PubMed ID: 38555401
[TBL] [Abstract][Full Text] [Related]
13. [Ranibizumab tachyphylaxis in a case of macular edema related to central retinal vein occlusion: Lasting effectiveness of switching to aflibercept].
Gambrelle J; Robinet A
J Fr Ophtalmol; 2017 Mar; 40(3):e83-e84. PubMed ID: 28318715
[No Abstract] [Full Text] [Related]
14. Aflibercept in exudative age related macular degeneration refractory to ranibizumab.
Ruiz Ramos J; Pascual-Camps I; Cuéllar-Monreal MJ; Dolz-Marco R; Fenoll MA; Font-Noguera I; Poveda-Andrés JL; Gallego-Pinazo R
Arch Soc Esp Oftalmol; 2015 Dec; 90(12):566-71. PubMed ID: 26515015
[TBL] [Abstract][Full Text] [Related]
15. [Switching to eylea in macular edema due to retinal vascular diseases].
Pascual-Camps I; Hernández-Martínez P; Ruiz J; Dolz-Marco R; Cuellar MJ; Gallego-Pinazo R
Arch Soc Esp Oftalmol; 2015 Jan; 90(1):48. PubMed ID: 25200895
[No Abstract] [Full Text] [Related]
16. Canadian preference and trends survey results for anti-VEGF treatment of macular edema.
Rayat JS; Grewal PS; Whelan J; Tennant MT; Choudhry N
Can J Ophthalmol; 2016 Jun; 51(3):233-7. PubMed ID: 27316276
[No Abstract] [Full Text] [Related]
17. Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life.
Schmid MK; Reich O; Faes L; Boehni SC; Bittner M; Howell JP; Thiel MA; Signorell A; Bachmann LM
PLoS One; 2015; 10(8):e0135050. PubMed ID: 26241852
[TBL] [Abstract][Full Text] [Related]
18. [Budget impact of the incorporation of second-line drug treatment for diabetic macular edema in the Brazilian Unified National Health System from the perspective of the Minas Gerais State Health Department, Brazil].
Izidoro JB; Piazza T; Andrade EIG; Alvares-Teodoro J
Cad Saude Publica; 2019 Aug; 35(8):e00145518. PubMed ID: 31460612
[TBL] [Abstract][Full Text] [Related]
19. Ziv-aflibercept in macular disease.
Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
[TBL] [Abstract][Full Text] [Related]
20. Cost Evaluation of Laser versus Intravitreal Aflibercept for Proliferative Diabetic Retinopathy.
Yannuzzi NA; Sridhar J; Chang JS; Lin J; Kuriyan AE; Smiddy WE
Ophthalmology; 2018 Jul; 125(7):1121-1122. PubMed ID: 29571831
[No Abstract] [Full Text] [Related]
[Next] [New Search]
